Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Skin Neoplasms × spartalizumab × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 4 Melanoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Locally Advanced Low Rectal Adenocarcinoma 1 HER2+ Breast Cancer 1 Epstein-Barr Virus Infections 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Colorectal Neoplasms 1

Interventions

Dacarbazine 4 pembrolizumab 3 binimetinib 3 encorafenib 2 cemiplimab 2 Ipilimumab 2 vitespin 1 trametinib 1 tilsotolimod 1 spartalizumab 1 oblimersen 1 lifileucel 1 gp100 Melanoma Antigen 1 dabrafenib 1 bempegaldesleukin 1 aldesleukin 1 Vinblastine 1 Vemurafenib 1 Tretinoin 1 Standard of Care 1 Sodium Chloride 1 Sirolimus 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Interleukin-2 1 Interferon-alpha 1 Interferon alpha-2 1 Injections 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡